A medical program in place of a subscription
Pasco's growth has been kind to homebuilders and hard on medical capacity. Bexley, Connerton, Wilderness Lake Preserve, the established neighborhoods around Lake Padgett: the population keeps compounding while the clinical infrastructure trails years behind it. The town's name is literal, a chain of lakes giving the area its shape, and the growth has poured in around them faster than any specialty could staff for. The med-spa industry noticed the mismatch before medicine did, which is why so much of the weight-loss marketing aimed at 34637, 34638, and 34639 arrives as a monthly subscription pitch.
It helps to say plainly what a subscription is optimized for, because it isn't you. It's retention arithmetic: the monthly charge continues as long as the friction stays low, so the model strips out everything that might interrupt the billing cycle, including the inconvenient lab result and the clinician empowered to say stop. A medical program carries the opposite incentive. We're paid to evaluate and to manage, which means finding things, saying no when no is the truthful answer, and adjusting course when your body votes.
The gap has a shape worth naming. Retail health arrived at the speed retail always moves, while physician capacity lagged years behind the rooftops it was meant to serve. Nobody planned it that way. It's simply what happens when a town doubles faster than its clinical infrastructure, and it's why so much local weight care now arrives by parcel carrier with no clinician attached to it. The medication is the easy part to ship. The evaluation, the monitoring, and the authority to stop are the parts that cannot be put in a box.
What the subscription can't include is the part that makes this medication defensible. Our flagship office at 27724 Cashford Circle, Suite 102, Wesley Chapel handles the in-person evaluation, and it offers what a shipping label can't: a physician who examines you, orders real bloodwork, reads it, and stays on the case through every dose change. Same-week appointments are the norm rather than the exception.
What we measure before anyone prescribes
The evaluation opens with a 45-minute visit, in person. Expect the whole weight story to get told: the year the trend started, every serious attempt since, the rebounds, the medications and life events tangled up in each chapter. Expect granular lifestyle questions too, sleep, activity, eating patterns, stress, plus a line-by-line pass through your current prescriptions, since a handful of common ones are quiet weight drivers.
Then the blood draw does its work. HbA1c and fasting glucose come first, because prediabetes and type 2 diabetes hide in plain sight. A comprehensive metabolic panel establishes how your kidneys and liver are doing before a new medication asks anything of them. Lipids sketch the cardiovascular backdrop. TSH rules the thyroid in or out as a contributor. Additional markers follow your history where it leads. A thyroid result alone redirects a surprising number of cases; so does a medication list with a quiet weight-driver on it. Neither shows up without the draw.
Two practical notes about the visit itself. First, bring your records if any exist: old labs, a recent physical, specialist notes, the actual bottles from your medicine cabinet. Documentation compresses weeks of discovery into minutes. Second, expect questions that feel adjacent to weight, about snoring, mood, energy, because the adjacent territory is where the real driver hides in a meaningful share of cases.
Safety screening runs in parallel and is non-negotiable: medullary thyroid carcinoma anywhere in the family, MEN2 syndrome, a past bout of pancreatitis, severe gastroparesis, an active eating disorder, pregnancy now or on the horizon. Sleep apnea and mood conditions get flagged for their own care. Under FDA labeling, the weight management indication generally fits adults with a BMI of 30 or above, or 27 and above with a related condition attached. The thresholds are a floor, not the whole decision: meeting a number establishes eligibility under the labeling, while the final call weighs the labs, the contraindications, the other conditions in play, and your own goals, which is why it belongs to a physician rather than an algorithm.
A follow-up rhythm a busy household can keep
Here's the piece designed specifically for how people in this town actually live. GLP-1 treatment is not one decision; it's a series of them, spaced across a titration schedule that climbs slowly for a reason. The opening weeks bring the most gastrointestinal turbulence, nausea, vomiting, diarrhea, constipation, and the difference between pushing through, pausing, and stopping is a clinical call that someone has to be present to make. Our follow-up cadence is calibrated to your dose steps, so the check-ins land exactly when the decisions do.
Sustainability is the quiet variable that decides most weight programs, and it's the one we design for hardest. A cadence that requires heroics collapses by spring. So the schedule bends to real life: video check-ins timed to dose changes, in-person visits when an exam genuinely adds something, lab rechecks driven by the clinical picture. If a week goes sideways, the plan flexes instead of breaking, because a missed appointment should trigger a reschedule, not a quiet exit from care. None of this cadence is punitive. It's the mechanism that catches a stall early, adjusts the dose before frustration sets in, and keeps the nutrition work honest between visits.
The schedule bends around the way households actually run instead of fighting it. After the initial in-person workup, established patients across 34637 through 34639 can take follow-ups by Florida telehealth, which turns a recurring appointment into a video visit that fits between obligations. And we plan for years, not weeks, because the honest arc of this treatment includes the ending: regain is the usual result of stopping unless eating, movement, and sleep genuinely changed along the way. Weight gets handled here like the chronic condition it is, with nutrition and lifestyle work running beside the medication from day one. The lifestyle half tends to succeed or fail at the household level anyway: what lands on the dinner table and when the walking happens are family variables, and plans built with the household in mind hold up longer than plans built for willpower in isolation. Results differ from person to person and depend on meeting clinical criteria, and we'd rather tell you that on a website than have you learn it from disappointment.
The people who should not be prescribed this, and what they get instead
Every clinic publishes who a GLP-1 is for. Far fewer publish who it is against, which is strange, because the second list is the one that decides whether a program is practicing medicine. Some of it is absolute. A personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia type 2, closes the door on this drug class entirely, and no amount of wanting it changes that. Current pregnancy, or pregnancy planned in the near term, is a stop. An active eating disorder is a stop, and pretending otherwise can cause real harm rather than merely fail to help. Severe gastroparesis is a stop, because the medication works partly by slowing the stomach further. A prior episode of pancreatitis is at minimum a hard pause that demands specialist input before anyone writes anything.
Then there is the larger group, and it surprises people: patients with nothing disqualifying at all, for whom this is simply the wrong first move. Untreated sleep apnea belongs in that group. It pushes weight up, wrecks the sleep that appetite regulation depends on, and treating it first sometimes changes the entire trajectory before a prescription is needed. So does a medication list doing the damage. Several widely used drugs across psychiatry, endocrinology, and neurology add weight steadily, and swapping one in coordination with the prescriber who started it is a smaller intervention with a better risk profile than layering a second drug on top. Undiagnosed thyroid disease belongs there too, along with a depression that has made every other change impossible to sustain.
What happens when the answer is no is the part that separates a practice from a storefront. A no here is never just a declined transaction, because we are the ones who have to keep caring for you afterward. It comes with the reason, the finding that produced it, and the next step: a sleep study order, a referral to endocrinology or gastroenterology, a coordinated medication change, a diabetes workup, or treatment for the mood condition that has been the real obstacle. Occasionally it is a temporary no with a date attached, a condition to stabilize first and a re-evaluation once it is stable, which is a different sentence than never.
Patients sometimes arrive braced for a fight about eligibility, because the market has trained them to expect a gate rather than an evaluation. The point is not to keep you from treatment. It is that a prescription written over the top of an unexamined problem does not solve the problem, it hides it for a year, and you are the one who pays for the hiding. Dr. Jason Saylor, DO makes those calls: board-certified in osteopathic family medicine, 17 years in practice, Chief Medical Officer at Ascend, with a working scope that spans weight loss management, chronic disease care including diabetes, hypertension, hyperlipidemia, and thyroid disease, and preventive medicine. He sees Land O' Lakes patients in person and, once they're established, across Florida by telehealth.
Dr. Jason Saylor, DO is the prescriber at both offices: board-certified in osteopathic family medicine, 17 years in practice, Chief Medical Officer at Ascend, with a working scope that spans weight loss management, chronic disease care including diabetes, hypertension, hyperlipidemia, and thyroid disease, and preventive medicine. He sees Land O' Lakes patients in person and, once they're established, across Florida by telehealth.
Land O' Lakes ZIPs & nearby areas we serve
- Land O' Lakes core: 34637, 34638, 34639 (covering Bexley, Connerton, Wilderness Lake Preserve, and Lake Padgett)
- Wesley Chapel: 33543, 33544, 33545 - see GLP-1 in Wesley Chapel
- Lutz: 33548, 33549, 33558, 33559 - see GLP-1 in Lutz
- Tampa proper: - see GLP-1 in Tampa
The rest of the picture: conditions that arrive with the weight
A thorough workup rarely comes back with a single finding, and the program is built to absorb what it finds. Type 2 diabetes pairs naturally with GLP-1 therapy, which can address both problems at once. Blood pressure that rose alongside the weight gets its medications reviewed rather than merely refilled. Cholesterol and metabolic syndrome numbers usually improve as weight falls, and the baseline draw is what makes that progress visible. An HbA1c between 5.7 and 6.4 percent means prediabetes, arguably the single best moment to intervene. MASLD, fatty liver disease by its older name, responds to weight reduction better than to any pill we could add.
There's a sequencing benefit to finding these conditions at the start rather than mid-program. A blood pressure medication adjusted in month one is a variable controlled before titration begins. A prediabetes diagnosis on day one reframes the goalposts from cosmetic to preventive. And a fatty liver finding gives the whole effort a second scoreboard, one measured in enzymes rather than pounds, which for many patients turns out to be the more motivating number. All of it lives in one chart at one practice, which is the quiet advantage of doing this through family medicine: the prescriber deciding your next dose is the same physician tracking your kidney function, your blood pressure trend, and the screenings you're due for anyway.
Paying for it: a straight answer instead of a pitch
No dollar amounts appear on this page, on purpose, because the honest answer depends on your plan and your visit type. What we can promise is the order of operations: benefits get verified before any prescription decision, and self-pay rates, which vary with the appointment type, any medication bundling, and the labs ordered, get confirmed by our billing team when you call (813) 670-3331. As of this writing, Dr. Saylor is in-network with Aetna, ChampVA, and UnitedHealthcare, and the billing team can confirm where your plan stands in that same call. Whether a plan pays for the GLP-1 medication itself turns on the indication, with weight management coverage frequently requiring prior authorization, and we run that process for you rather than leaving it at the pharmacy counter.
The order of operations exists because this drug class has a well-earned reputation for coverage surprises. Indication decides everything: the identical molecule can clear authorization under one diagnosis and stall under another, and plans rewrite their rules yearly. We'd rather spend twenty minutes on verification than have you spend a month on an appeal, so the phone call comes first.
If the hardest part of getting real medical weight care has been finding a clinic that reads the labs before it writes anything, that's a solvable problem. Book online or dial (813) 670-3331; the first opening is usually this week. Bring your questions, bring your records, and bring your skepticism about the subscription ads. All three will be put to good use.
FAQs about GLP-1 weight loss in Land O' Lakes
Who does not get prescribed a GLP-1 here?
Two groups. The first has an absolute contraindication the screen exists to find: a personal or family history of medullary thyroid carcinoma, MEN2 syndrome, current or near-term pregnancy, an active eating disorder, severe gastroparesis, or a prior pancreatitis episode. The second has nothing disqualifying but a better first move available, most often untreated sleep apnea, a thyroid problem, or a current medication that is adding the weight. Both groups leave with the finding, the reason, and the next step rather than a declined checkout.
What happens if I miss a follow-up?
You reschedule, and nothing silently lapses. A missed appointment should trigger a phone call, not a quiet exit from care, and the plan is built to flex when a week goes sideways. The failure mode we design against is the patient who drifts out of contact while the medication keeps arriving.
Can follow-ups happen outside school and work hours?
That is much of the reason established patients move to Florida telehealth. A titration visit from a kitchen table does not require leaving work early or rearranging a pickup line. Ask when you book and the front desk will fit the cadence to how your week actually runs.
My spouse and I both want to be evaluated. Is that possible?
Yes, as two separate evaluations. Each person needs their own history, their own panel, and their own candidacy decision, because the findings frequently differ more than couples expect. Scheduling them near each other is usually straightforward.
Does the program still work if my schedule is unpredictable?
It is built for that. One in-person visit anchors the case; the rest is designed to survive a chaotic calendar. What actually derails these programs is not a missed week, it is a long gap where nobody is watching the dose while the medication keeps shipping.
How is the follow-up rhythm decided?
By your titration schedule and your tolerance, not by a subscription date. Dose steps set the checkpoints, symptoms can pull the next one forward, and lab rechecks are ordered when the picture warrants. The prescriber sets that rhythm and changes it when your case changes.
What actually makes people drop out of these programs?
Two things, usually. The first eight weeks are the hardest and the gastrointestinal effects are real, so a dose step taken too fast can end a program that would otherwise have worked. The second is losing contact with a clinician, at which point nobody is left to distinguish a side effect worth managing from one worth stopping for.
Do I have to switch my primary care to Ascend?
No. Some patients keep an existing physician and use us for the weight program; others consolidate because the metabolic chart and the weight chart are the same chart. Either way we coordinate medication changes rather than working around whoever else is prescribing.
The subscription ads offer a compounded product. Do you?
Rarely, and never as the opening move. What those ads are selling is the default of their business model; here it is an exception a physician has to document an individual medical need for. It matters that you know the difference: compounded semaglutide and tirzepatide are not FDA-approved, whereas the commercially manufactured products carry FDA approval for their labeled uses.
Compounded semaglutide and tirzepatide, prepared by a licensed pharmacy when there is a documented individual medical need, are not FDA-approved. Common side effects include nausea, vomiting, diarrhea, and constipation, particularly during dose titration. Serious risks include pancreatitis, gallbladder disease, and possible worsening of certain conditions. Weight loss results vary substantially. This page is informational and does not substitute for a clinical visit. See FDA prescribing information for semaglutide and tirzepatide products, available via FDA Drugs@FDA.